# Effects of placental cord drainage in the third stage of labour: A meta-analysis

Hang-lin Wu<sup>1\*</sup>, Xiao-wen Chen<sup>1</sup>, Pei Wang<sup>1</sup>, Qiu-meng Wang<sup>1</sup>

China. Correspondence and requests for materials should be addressed to H.L.W. (email:

hanglinwu@gmail.com)

<sup>&</sup>lt;sup>1</sup> Department of Obstetrics and Gynaecology, Hangzhou Women's Hospital, Hangzhou, Zhejiang,


## Supplementary Appendix S2. Detailed search strategy for the meta-analysis

Databases searched	PubMed, Embase, the Cochrane Library, Web of Science and Google Scholar.
Search strategy for Pubmed	(((((((cord) OR placenta*) AND drain*)) OR Drainage[MeSH Terms])) AND (((((((stage) OR Stages) AND (((third) OR 3) OR 3rd)))) OR ((((((((((((((((((((((((((((((((
Other sources	50 related journals were also searched, the majority of which are currently on the initiative lists of Core Outcomes in Women's and Newborn Health. The reference lists of the selected articles and reviews were hand searched to identify any other relevant articles.

Journals searched are the following:

- 1. Acta Obstetricia et Gynecologica Scandinavica
- 2. American Journal of Obstetrics & Gynecology
- 3. American Journal of Perinatology
- 4. Australian and New Zealand Journal of Obstetrics and Gynaecology
- 5. Best Practice & Research: Clinical Obstetrics & Gynaecology
- 6. Birth: Issues in Perinatal Care
- 7. BJOG: An International Journal of Obstetrics and Gynaecology
- 8. BMC Pregnancy and Childbirth
- 9. BMC Women's Health
- 10. Clinical Obstetrics and Gynecology
- 11. Clinics in Perinatology
- 12. Cochrane Gynaecology and Fertility Group
- 13. Cochrane Fertility Regulation Group
- 14. Cochrane Pregnancy and Childbirth Group
- 15. Contraception
- 16. Current Obstetrics and Gynecology Reports
- 17. Current Opinion in Obstetrics and Gynecology
- 18. European Journal of Obstetrics & Gynecology and Reproductive Biology
- 19. Fertility and Sterility

- 20. Fertility Research and Practice
- 21. Female Pelvic Medicine and Reconstructive Surgery
- 22. Fetal Diagnosis and Therapy
- 23. Geburtshilfe & Frauenheikunde
- 24. Ginekologia Polska
- 25. Gynecological Surgery
- 26. Gynecologic and Obstetric Investigation
- 27. Gynecologic Oncology
- 28. Human Fertility
- 29. Human Reproduction
- 30. International Journal of Gynecology & Obstetrics
- 31. Journal de Gynecologie Obstétrique et Biologie de la Reproduction
- 32. Journal of Obstetrics and Gynecology of India
- 33. Journal of Midwifery & Women's Health
- 34. Journal of Obstetrics & Gynaecology
- 35. Journal of Obstetrics and Gynaecology Canada
- 36. Journal of Obstetrics and Gynaecology Research
- 37. Journal of Obstetric, Gynecologic & Neonatal Nursing
- 38. Maternal Health, Neonatology and Perinatology
- 39. Midwifery
- 40. Nederlands Tijdschrift voor Obstetrie en Gynaecologie (NTOG)
- 41. New Zealand College of Midwives Journal
- 42. Obstetrics & Gynecology
- 43. Placenta
- 44.Post Reproductive Health
- 45. Reproductive Health
- 46. Russian Journal of Obstetrics and Gynaecology
- 47.Shiraz E Medical Journal
- 48. Women and Birth
- 49. Women's Midlife Health
- 50. Medical Journal of Srisaket Surin Buriram Hospitals



Supplementary Appendix S3. Risks of bias of included studies. The plus sign indicates a low risk of bias; the minus sign indicates a high risk of bias; the question mark indicates an unclear risk of bias.

Supplementary Table S1. All data underlying the findings in the manuscript

manascript							
		Thi	rd stage o	duration(r	min)		
Study	Year	Tsample	Tmean	Tsd	Csample	Cmean	Csd
Sharma	2005	478	3.22	2.82	480	6.99	2.86
Shravage	2007	100	5.02	1.71	100	7.42	2.56
Jongkolsiri	2009	49	5.1	2.4	50	7	6.1
Makvandi	2013	50	3.54	0.91	51	5.16	1.13
Sattamai	2013	50	2.4	1.8	50	3.6	1.8
Amorim	2015	113	14	13	113	14	12
Asicioglu	2015	242	3.5	1.9	243	7.7	3.4
Roy	2016	100	3.51	1.39	100	5.04	1.57
		Av	erage blo	od loss(r	ml)		
Study	Year	Tsample	Tmean	Tsd	Csample	Cmean	Csd
Shravage	2007	100	175.05	118.15	100	252.05	145.48
_ankeshwara	2008	117	222	208	117	141	101
Sattamai	2013	50	261.18	111.41	50	331.4	180.29
Amorim	2015	113	248	254	113	208	187
Asicioglu	2015	242	207.04	123.3	243	277.63	246.9
Rov	2016	100	227.5	75.3	100	313.3	81.7
		Incidence	of Postp	artum he	morrhage		
Study	Year				Cevent		
Sharma	2005	38	440	478	41	439	480
Shravage	2007	3	97	100	10	90	100
Jongkolsiri	2009	0	49	49	0	50	50
Sattamai	2013	2	48	50	7	43	50
Asicioglu	2015	8	234	242	16	227	243
Roy	2016	1	99	100	9	91	100
	200000				oval of pla	and the same of th	
Study	Year				e Cevent		1.00
Sharma	2005	0	478	478	0	480	480
Shravage	2007	0	100	100	0	100	100
Jongkolsiri	2009	0	49	49	1	49	50
Makvandi	2013	0	50	50	0	51	51
Asicioglu	2015	0	242	242	0	243	243
			355330102047 33	nsfusion			
Study	Year	Tevent	Tnoevent			Cnoevent	
Sharma	2005	7	471	478	9	471	480
Jongkolsiri	2009	0	49	49	0	50	50
Asicioglu	2015	4	238	242	12	231	243


C	Change of maternal hemoglobin after delivery(mg/dl)						
Study	Year	Tsample	Tmean	Tsd	Csample	Cmean	Csd
_ankeshwara	2008	117	1.3	0.7	117	1	0.6
Roy	2016	100	0.6	0.3	100	1.1	0.25
	Р	re-partun	n materna	l hemogle	obin(mg/d	II)	717
Study	Year	Tsample	Tmean	Tsd	Csample	Cmean	Csd
Asicioglu	2015	242	10.9	0.9	243	11	1.1
Roy	2016	100	10.2	0.56	100	9.9	0.58
	Р	ostpartun	n materna	l hemogl	obin(mg/d	II)	
Study	Year	Tsample	Tmean	Tsd	Csample	Cmean	Csd
Asicioglu	2015	242	9.8	1	243	9.1	0.9
Roy	2016	100	9.6	0.62	100	8.8	0.71
		Addition	al uteroto	nic drugs	required		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Study	Year	Tevent	Tnoevent	Tsample	Cevent	Cnoeven	tCsample
Shravage	2007	3	97	100	7	93	100
Asicioglu	2015	5	237	242	16	227	243
Adverse events at time of drainage							
Study	Year	Tevent	Tnoevent	Tsample	Cevent	Cnoeven	tCsample
Asicioglu	2015	0	242	242	0	243	243

Abbreviations: Tsample, Sample size of treatment group; Csample, Sample size of control group; Tevent, Number of events happened in treatment group; Tnoevent, Number of samples without event occurred in treatment group; Cevent, Number of events happened in control group; Cnoevent, Number of samples without event occurred in control group; Tmean, Mean of results in treatment group; Tsd, Standard deviation of results in treatment group; Cmean, Mean of results in control group; Csd, Standard deviation of results in control group.

### Supplementary Figure S1. Comparison of cord drainage versus no drainage (all)


Outcome:Incidence of postpartum haemorrhage(A:risk ratio,B:risk difference)

Α



## Supplementary Figure S2 . Comparison of cord drainage versus no drainage (all) Outcome:Retained placenta or manual removal of placenta(A:risk ratio,B:risk difference)

#### Α



#### В

Study		RD(95%CI)	Weight
Sharma (2005)	+	0.00 (-0.00, 0.00)	75.79
Shravage (2007)		0.00 (-0.02, 0.02)	3.37
Jongkolsiri (2009)	<u> </u>	-0.02 (-0.07, 0.03)	0.43
Makvandi (2013)		0.00 (-0.04, 0.04)	0.88
Asicioglu (2015)	-	0.00 (-0.01, 0.01)	19.52
Overall (I–squared = 0.0%, p = 0.935)	$\Diamond$	-0.00 (-0.00, 0.00)	100.00
NOTE: Weights are from random effects analysis			
1 074 <b>C</b> 6	ord drainage 0 No drainage	.074	

# Supplementary Figure S3 . Comparison of cord drainage versus no drainage (all)

Outcome: Need for blood transfusion(A:risk ratio, B:risk difference)

## Α


Study	RR(95%CI)	Weight
Sharma (2005)	0.78 (0.29, 2.08)	55.22
Asicioglu (2015)	0.33 (0.11, 1.02)	44.78
Jongkolsiri (2009)	(Excluded)	0.00
Overall (I–squared = 20.3%, p = 0.263)	0.53 (0.23, 1.22)	100.00
NOTE: Weights are from random effects analysis		
.109 Cord drainage No drainag	9.13	

## В

Study			RD(95%CI)	Weight
Sharma (2005)	-		-0.00 (-0.02, 0.01)	54.34
Jongkolsiri (2009)		•	0.00 (-0.04, 0.04)	19.47
Asicioglu (2015)	•	-	-0.03 (-0.06, -0.00)	26.19
Overall (I-squared = 35.1%, p = 0.214)			-0.01 (-0.03, 0.01)	100.00
NOTE: Weights are from random effects	analysis			
0645	Cord drainage	No drainage	.0645	


### Supplementary Figure S4. Comparison of cord drainage versus no drainage (all)

Outcome:prepartum hemoglobin(Hb) and postpartum hemoglobin(Hb)



### Supplementary Figure S5. Comparison of cord drainage versus no drainage (all)


Outcome:Changes in maternal haemoglobin after delivery




# Supplementary Figure S6. Comparison of cord drainage versus no drainage (all)

Outcome: Additional uterotonic drugs required (A:risk ratio, B:risk difference)


Α




В



# Supplementary Figure S7 . Comparison of cord drainage versus no drainage (all) Outcome:Length of the third stage of labour



# Supplementary Figure S8. Comparison of cord drainage versus no drainage (all) Outcome: Average blood loss




### Supplementary Figure S9. Comparison of cord drainage versus no drainage (\*)

Outcome:Length of the third stage of labour

Study		WMD (95%CI) Weight
Sharma (2005) ————		-3.77 (-4.13, -3.41) 15.30
Shravage (2007)	<u> </u>	-2.40 (-3.00, -1.80) 14.74
Jongkolsiri (2009)	•	-1.90 (-3.72, -0.08) 10.07
Makvandi (2013)	-	-1.62 (-2.02, -1.22) 15.23
Sattamai (2013)		-1.20 (-1.91, -0.49) 14.43
Asicioglu (2015)		-4.20 (-4.69, -3.71) 15.03
Roy (2016)	-	-1.53 (-1.94, -1.12) 15.20
Overall (I-squared = 95.9%, p = 0.000)		-2.41 (-3.37, -1.44) 100.00
NOTE: Weights are from random effects anal		
-4.69	Cord drainage 0	No drainage 4.69

<sup>\*</sup>Sensitivity analysis by excluding Amorim 2015 (The article did not clarify rational random sequence generation and reported the third stage duration with outliers)

# Supplementary Figure S10 . Comparison of cord drainage versus no drainage (\*) Outcome: Average blood loss



<sup>\*</sup>Sensitivity analysis by excluding Amorim 2015 and Lankeshwara 2008 (The articles did not clarify rational random sequence generation)

Supplementary Table S2. Cord drainage versus no drainage: subgroups according to the mode of birth (normal vaginal birth versus mixed with assisted vaginal birth)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size	Heterogeneity (I <sup>2</sup> )
1.Third stage					
duration					
•normal vaginal birth	6	1362	MD(IV, Random, 95% CI)	-2.05(-3.07,-1.03)	94.6%
•mixed with assisted vaginal birth	2	1057	MD (IV, Random, 95% CI)	-3.06(-4.84,-1.28)	74.4%
2.Incidence of					
postpartum					
haemorrhage			RR (M-H, Random, 95% CI)	0.36(0.20,0.65)	0.0%
•normal vaginal birth	4	1035	RD (M-H, Random, 95% CI)	-0.05(-0.08,-0.03)	0.0%
•mixed with assisted	_		RR (M-H, Random, 95% CI)	0.93(0.61,1.42)	Not available
vaginal birth	2	1057	RD (M-H, Random, 95% CI)	0.00(-0.03,0.02)	0.0%
3.Retained placenta					
1 ' 11' /1	2	706	RR (M-H, Random, 95% CI)	Excluded	Not available
•normal vaginal birth	3	786	RD (M-H, Random, 95% CI)	0.00(-0.01,0.01)	0.0%
•mixed with assisted	2	1057	RR(M-H, Random, 95% CI)	0.34(0.01,8.15)	Not available
vaginal birth	2	1057	RD (M-H, Random, 95% CI)	0.00(-0.02,0.02)	19.5%
4.Blood transfusion					
moment versional Islants	1	105	RR (M-H, Random, 95% CI)	0.34(0.11,1.02)	Not available
•normal vaginal birth	1	485	RD (M-H, Random, 95% CI)	-0.03(-0.06,0.00)	Not available
•mixed with assisted	2	1057	RR(M-H, Random, 95% CI)	0.78(0.29,2.08)	Not available
vaginal birth	2	1057	RD (M-H, Random, 95% CI)	0.00(-0.02,0.01)	0.0%

Abbreviations: MD, Mean Difference; RR, Risk Ratio; RD, Risk Difference; IV, Inverse Variance; M-H, Mantel-Haenszel.

Supplementary Table S3. Cord drainage versus no drainage: subgroups according to the use of uterotonics in the third of stage of labour (use of uterotonics versus non-use of uterotonics)

Outcome or	No. of	No. of	Statistical method Effect size		Heterogeneity
subgroup title	studies	participants			$(I^2)$
1.Third stage					
duration					
•use of	4	1793	MD (IV, Random, 95% CI)	-2.69 (-4.12, -1.25)	97.4%
•non-use of					
uterotonics	2	301	MD (IV, Random, 95% CI)	-1.98 (-2.74, -1.21)	77.6%
2.Average					
blood loss					
•use of					
uterotonics	3	835	MD (IV, Random, 95% CI)	-80.49(-98.09 ,-62.89)	0.0%
•non-use of	1	200	MD (NLD 1 050) CD	77.00/ 112.72 40.27	N. 111
uterotonics	1	200	MD (IV, Random, 95% CI)	-77.00(-113.73,-40.27)	Not available
3.Incidence of					
postpartum					
haemorrhage					
•use of	4	1702	RR (M-H, Random, 95% CI)	0.51(0.24, 1.08)	56.7%
uterotonics	4	1793	RD (M-H, Random, 95% CI)	-0.04(-0.08,0.00)	51.7%
•non-use of	1	200	RR (M-H, Random, 95% CI)	0.30(0.09, 1.06)	Not available
uterotonics	1	200	RD (M-H, Random, 95% CI)	-0.07(-0.14,0.00)	Not available
4.Retained					
placenta					
•use of	2	1443	RR (M-H, Random, 95% CI)	Not available	Not available
uterotonics	2	1443	RD (M-H, Random, 95% CI)	0.00(0.00, 0.00)	0.0%
•non-use of	2	201	RR (M-H, Random, 95% CI)	Not available	Not available
uterotonics	2	301	RD (M-H, Random, 95% CI)	0.00(-0.02,0.02)	0.0%
5.Additional					
uterotonic					
drugs needed					
•use of		407	RR (M-H, Random, 95% CI)	0.31(0.12, 0.84)	Not available
uterotonics	1	485	RD (M-H, Random, 95% CI)	-0.05(-0.08,-0.01)	Not available
•non-use of	_	• • • •	RR (M-H, Random, 95% CI)	0.43(0.11, 1.61)	Not available
uterotonics	1	200	RD (M-H, Random, 95% CI)	-0.04(-0.10,0.02)	Not available

Abbreviations: MD, Mean Difference; RR, Risk Ratio; RD, Risk Difference; IV, Inverse Variance; M-H, Mantel-Haenszel.

Supplementary Table S4. Cord drainage versus no drainage: subgroups according to parturition history( primigravida versus mixed with multigravida)

Outcome or	No. of	No. of	Statistical method	Effect size	Heterogeneity
subgroup title	studies	participants			$(I^2)$
1.Third stage					
duration					
<ul><li>Primigravida</li></ul>	2	421	MD(IV, Random, 95% CI)	-2.70(-4.80, -0.59)	98.4%
<ul><li>Mixed with</li></ul>	6	1360	MD(IV, Random, 95% CI)	-2.09(-3.29, -0.89)	93.9%
multigravida	0	1300	WID(1 v, Random, 95% C1)	-2.07(-3.27, -0.07)	73.770
2.Incidence of					
postpartum					
haemorrhage					
<ul> <li>Primigravida</li> </ul>	1	320	RR (M-H, Random, 95% CI)	0.93(0.61, 1.42)	Not available
●Pillingravida	1	320	RD (M-H, Random, 95% CI)	-0.01(-0.04,0.03)	Not available
<ul><li>Mixed with</li></ul>	_	1124	RR(M-H, Random, 95% CI)	0.36(0.20, 0.65)	0.0%
multigravida	5	1134	RD (M-H, Random, 95% CI)	-0.05(-0.08,-0.01)	58.6%
3.Retained					_
placenta					
<ul> <li>Primigravida</li> </ul>	2	421	RR(M-H, Random, 95% CI)	Not available	Not available
●FIIIIIgravida	2	421	RD (M-H, Random, 95% CI)	0.00(0.00,0.00)	0.0%
<ul><li>Mixed with</li></ul>	2	704	RR(M-H, Random, 95% CI)	0.34(0.01, 8.15)	Not available
multigravida	3	784	RD (M-H, Random, 95% CI)	0.00(-0.01,0.01)	0.0%
4.Blood					
transfusion					
Duimi anavid-	1	220	RR(M-H, Random, 95% CI)	0.78(0.29, 2.08)	Not available
<ul><li>Primigravida</li></ul>	1	320	RD (M-H, Random, 95% CI)	0.00(-0.02,0.01)	Not available
<ul><li>Mixed with</li></ul>	2	<b>5</b> 04	RR(M-H, Random, 95% CI)	0.33(0.11, 1.02)	Not available
multigravida	2	584	RD (M-H, Random, 95% CI)	-0.02(-0.05,0.02)	50.9%

Abbreviations: MD, Mean Difference; RR, Risk Ratio; RD, Risk Difference; IV, Inverse Variance; M-H, Mantel-Haenszel.